{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:52:22Z","timestamp":1790268742616,"version":"4.1.0"},"reference-count":135,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cancer remains a leading cause of death globally. Cancer patients often seek alternative therapies in addition to, or instead of, conventional treatments like chemotherapy, radiation, and surgery. The progress in medical advancements and early detection provides more treatment options; however, the development of cancer drugs requires a significant amount of time, demands substantial investments, and results in an overall low percent of regulatory approval. The complex relationship between patent protection and pharmaceutical innovation complicates cancer drug development and contributes to high mortality rates. Adjusting patent criteria for alternative cancer therapeutics could stimulate innovation, enhance treatment options, and ultimately improve outcomes for cancer patients. This article explores the potential of alternative cancer therapeutics, chemopreventive agents, natural products, off-patent drugs, generic unpatentable chemicals, and repurposed drugs in cancer treatment, emphasizing the mechanisms and therapeutic potential of these unconventional compounds as combinatorial cancer therapies. The biological pathways, therapeutic effects, and potential to enhance existing therapies are reviewed, demonstrating their cost-effective and accessible options as adjuvant cancer therapies.<\/jats:p>","DOI":"10.3390\/pharmaceutics16091237","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T03:49:46Z","timestamp":1727149786000},"page":"1237","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Alternative Cancer Therapeutics: Unpatentable Compounds and Their Potential in Oncology"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1271-1099","authenticated-orcid":false,"given":"Dmitriy","family":"Ovcharenko","sequence":"first","affiliation":[{"name":"Altogen Labs, 11200 Menchaca Road, Austin, TX 78748, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Mukhin","sequence":"additional","affiliation":[{"name":"Altogen Labs, 11200 Menchaca Road, Austin, TX 78748, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Ovcharenko","sequence":"additional","affiliation":[{"name":"Altogen Labs, 11200 Menchaca Road, Austin, TX 78748, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/2231-4040.82952","article-title":"Intellectual property rights: An overview and implications in pharmaceutical industry","volume":"2","author":"Saha","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1353\/pbm.1995.0053","article-title":"The development and dissemination of non-patentable therapies (NPTs)","volume":"39","year":"1995","journal-title":"Perspect. Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.fct.2016.11.001","article-title":"An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series","volume":"107","author":"Brown","year":"2017","journal-title":"Food Chem. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gold, E.R., Kaplan, W., Orbinski, J., Harland-Logan, S., and N-Marandi, S. (2010). Are patents impeding medical care and innovation?. PLoS Med., 7.","DOI":"10.1371\/journal.pmed.1000208"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1743-7075-7-7","article-title":"Cancer as a metabolic disease","volume":"7","author":"Seyfried","year":"2010","journal-title":"Nutr. Metab."},{"key":"ref_9","unstructured":"Dyvik, E.H. (2024, August 03). International Intellectual Property Index 2023. Available online: https:\/\/www.statista.com\/statistics\/257583\/gipc-international-intellectual-property-index."},{"key":"ref_10","unstructured":"US Chamber of Commerce (2024, August 03). International IP Index. Available online: https:\/\/www.uschamber.com\/assets\/documents\/GIPC_IPIndex2023_FullReport_final.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hinkson, I.V., Madej, B., and Stahlberg, E.A. (2020). Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00770"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1097\/MS9.0000000000001315","article-title":"The prevalence and pattern of complementary and alternative medicine use among cancer patients in a tertiary oncology center: A cross-sectional study","volume":"85","author":"Almouaalamy","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.3747\/co.25.3884","article-title":"Complementary and alternative medicine use in patients before and after a cancer diagnosis","volume":"25","author":"Buckner","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"a020933","DOI":"10.1101\/cshperspect.a020933","article-title":"Research use exemptions to patent infringement for drug discovery and development in the United States","volume":"5","author":"Russo","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/acs.jmedchem.3c02165","article-title":"A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs","volume":"67","author":"Brown","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chirmule, N., Feng, H., Cyril, E., Ghalsasi, V.V., and Choudhury, M.C. (2024). Orphan drug development: Challenges, regulation, and success stories. J. Biosci., 49.","DOI":"10.1007\/s12038-024-00425-y"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/1574892818666221104113703","article-title":"Prospective Challenges for Patenting and Clinical Trials of Anticancer Compounds from Natural Products: Coherent Review","volume":"18","author":"Sahoo","year":"2023","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.drudis.2022.06.001","article-title":"Multiple deadlocks in the development of nonprofit drugs","volume":"27","author":"Cvek","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21131","DOI":"10.3402\/jmahp.v1i0.21131","article-title":"Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: Reassessment of nomenclature","volume":"1","author":"Murteira","year":"2013","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e17488","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"Ezike","year":"2023","journal-title":"Heliyon"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","article-title":"Controlled drug delivery systems: Past forward and future back","volume":"190","author":"Park","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Singh, A.K., Kumar, A., Singh, H., Sonawane, P., Paliwal, H., Thareja, S., Pathak, P., Grishina, M., Jaremko, M., and Emwas, A.H. (2022). Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091071"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural Products as Sources of New Drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12672-023-00758-4","article-title":"A target map of clinical combination therapies in oncology: An analysis of clinicaltrials.gov","volume":"14","author":"Yang","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"118134","DOI":"10.1016\/j.lfs.2020.118134","article-title":"Combinatorial drug therapy in cancer\u2014New insights","volume":"258","author":"Bhatia","year":"2020","journal-title":"Life Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Banerji","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13063-021-05273-x","article-title":"Exploring new uses for existing drugs: Innovative mechanisms to fund independent clinical research","volume":"22","author":"Verbaanderd","year":"2021","journal-title":"Trials"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","article-title":"Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer","volume":"1871","author":"Scapozza","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ferreira, A.M.D.C., Schneider-Stock, R., and Aiello, F. (2022). Editorial: Design, Synthesis, and Preclinical Testing of Innovative Anti-Cancer Compounds with a High Level of Selectivity of Action and Low Toxicity. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.859821"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dogra, A., and Kumar, J. (2023). Biosynthesis of anticancer phytochemical compounds and their chemistry. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1136779"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1093\/oncolo\/oyad084","article-title":"Communication About Complementary and Alternative Medicine When Patients Decline Conventional Cancer Treatment: Patients\u2019 and Physicians\u2019 Experiences","volume":"28","author":"Wode","year":"2023","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12032-022-01677-0","article-title":"Innovation in cancer therapeutics and regulatory perspectives","volume":"39","author":"Sharma","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.7326\/M24-0377","article-title":"The Ethics of Cancer Screening Based on Race and Ethnicity","volume":"177","author":"Doubeni","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shankar, G.M., Swetha, M., Keerthana, C.K., Rayginia, T.P., and Anto, R.J. (2022). Cancer Chemoprevention: A Strategic Approach Using Phytochemicals. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.809308"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.tips.2005.04.004","article-title":"Dietary cancer-chemopreventive compounds: From signaling and gene expression to pharmacological effects","volume":"26","author":"Chen","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_38","first-page":"51","article-title":"Dietary phytochemicals and their role in cancer chemoprevention","volume":"7","author":"Kumar","year":"2021","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_39","first-page":"394","article-title":"Dietary derived compounds in cancer chemoprevention","volume":"16","author":"Langner","year":"2012","journal-title":"Contemp. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ding, Y., Hou, R., Yu, J., Xing, C., Zhuang, C., and Qu, Z. (2023). Dietary Phytochemicals as Potential Chemopreventive Agents against Tobacco-Induced Lung Carcinogenesis. Nutrients, 15.","DOI":"10.3390\/nu15030491"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1427S","DOI":"10.1093\/ajcn\/62.6.1427S","article-title":"Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study","volume":"62","author":"Albanes","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJM199605023341802","article-title":"Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease","volume":"334","author":"Omenn","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.lungcan.2012.04.015","article-title":"Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in the VITAL study","volume":"77","author":"Brasky","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10142-008-0102-y","article-title":"Protein kinases controlling PCNA and p53 expression in human ovarian cells","volume":"9","author":"Sirotkin","year":"2009","journal-title":"Funct. Integr. Genom."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0076-6879(04)92015-0","article-title":"High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: Functional genomics investigations of biological pathways","volume":"392","author":"Sachse","year":"2005","journal-title":"Methods Enzymol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1677\/JME-08-0179","article-title":"Identification of protein kinases that control ovarian hormone release by selective siRNAs","volume":"44","author":"Sirotkin","year":"2010","journal-title":"J. Mol. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10142-014-0413-0","article-title":"MicroRNAs control transcription factor NF-kB (p65) expression in human ovarian cells","volume":"15","author":"Sirotkin","year":"2015","journal-title":"Funct. Integr. Genom."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hewlings, S.J., and Kalman, D.S. (2017). Curcumin: A Review of Its Effects on Human Health. Foods, 6.","DOI":"10.3390\/foods6100092"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Giordano, A., and Tommonaro, G. (2019). Curcumin and Cancer. Nutrients, 11.","DOI":"10.3390\/nu11102376"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Cione, E., La Torre, C., Cannataro, R., Caroleo, M.C., Plastina, P., and Gallelli, L. (2019). Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation. Molecules, 25.","DOI":"10.3390\/molecules25010063"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semcancer.2020.05.011","article-title":"Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement","volume":"80","author":"Aggarwal","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/fsn3.855","article-title":"Resveratrol: A miraculous natural compound for diseases treatment","volume":"6","author":"Koushki","year":"2018","journal-title":"Food Sci. Nutr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/01635581.2012.654926","article-title":"Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer","volume":"64","author":"Zhu","year":"2012","journal-title":"Nutr. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zou, Y., Zhang, G., Li, C., Long, H., Chen, D., Li, Z., Ouyang, G., Zhang, W., Zhang, Y., and Wang, Z. (2023). Discovery of Tryptanthrin and Its Derivatives and Its Activities against NSCLC In Vitro via Both Apoptosis and Autophagy Pathways. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021450"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1039\/D3MD00698K","article-title":"Recent advances of tryptanthrin and its derivatives as potential anticancer agents","volume":"15","author":"Zhou","year":"2024","journal-title":"RSC Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kaur, S., Mendonca, P., and Soliman, K.F.A. (2024). The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer. Nutrients, 16.","DOI":"10.3390\/nu16152392"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/01635581.2015.1002625","article-title":"The chemopreventive effect of the dietary compound kaempferol on the MCF-7 human breast cancer cell line is dependent on inhibition of glucose cellular uptake","volume":"67","author":"Azevedo","year":"2015","journal-title":"Nutr. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ptr.6858","article-title":"Ginger (Zingiber officinale Rosc.) and its bioactive components are potential resources for health beneficial agents","volume":"35","author":"Zhang","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Furlan, V., and Bren, U. (2020). Protective Effects of [6]-Gingerol Against Chemical Carcinogens: Mechanistic Insights. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030695"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3892\/or.2015.4405","article-title":"10-Gingerol inhibits proliferation and invasion of MDA-MB-231 breast cancer cells through suppression of AKT and p38MAPK activity","volume":"35","author":"Joo","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1038\/cddis.2013.26","article-title":"Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil","volume":"4","author":"Vinod","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/01635581.2021.1889622","article-title":"Identification of Potential Therapeutic Genes and Pathways in Phytoestrogen Emodin Treated Breast Cancer Cell Lines via Network Biology Approaches","volume":"74","author":"Guray","year":"2022","journal-title":"Nutr. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Stompor-Gor\u0105cy, M. (2021). The Health Benefits of Emodin, a Natural Anthraquinone Derived from Rhubarb-A Summary Update. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179522"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10238-020-00677-6","article-title":"Zinc as a complementary treatment for cancer patients: A systematic review","volume":"21","author":"Hoppe","year":"2021","journal-title":"Clin. Exp. Med."},{"key":"ref_65","first-page":"2750","article-title":"Forgiftning med arsen [Arsenic poisoning]","volume":"124","author":"Olsen","year":"2004","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/bit.28728","article-title":"Synthesized arsenic nanoparticles and their high potential in biomedical applications: A review","volume":"121","author":"Hosseininasab","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1039\/D1CS00933H","article-title":"Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases","volume":"51","author":"Lu","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Yue, S., Luo, M., Liu, H., and Wei, S. (2020). Recent Advances of Gold Compounds in Anticancer Immunity. Front. Chem., 8.","DOI":"10.3389\/fchem.2020.00543"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Radomska, D., Czarnomysy, R., Radomski, D., and Bielawski, K. (2021). Selenium Compounds as Novel Potential Anticancer Agents. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031009"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/ars.2011.4145","article-title":"The role of selenium in inflammation and immunity: From molecular mechanisms to therapeutic opportunities","volume":"16","author":"Huang","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ji, P., Wang, P., Chen, H., Xu, Y., Ge, J., Tian, Z., and Yan, Z. (2023). Potential of Copper and Copper Compounds for Anticancer Applications. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020234"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Molinaro, C., Martoriati, A., Pelinski, L., and Cailliau, K. (2020). Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II. Cancers, 12.","DOI":"10.3390\/cancers12102863"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Li, Y., and Lin, W. (2023). Platinum-based combination nanomedicines for cancer therapy. Curr. Opin. Chem. Biol., 74.","DOI":"10.1016\/j.cbpa.2023.102290"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ausina, P., Branco, J.R., Demaria, T.M., Esteves, A.M., Leandro, J.G.B., Ochioni, A.C., Mendon\u00e7a, A.P.M., Palhano, F.L., Oliveira, M.F., and Abou-Kheir, W. (2020). Acetylsalicylic acid and salicylic acid present anticancer properties against melanoma by promoting nitric oxide-dependent endoplasmic reticulum stress and apoptosis. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-76824-6"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/15384047.2022.2104561","article-title":"Colorectal cancer chemoprevention: Is aspirin still in the game?","volume":"23","author":"Grancher","year":"2022","journal-title":"Cancer Biol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Liu, C., Chen, H., Hu, B., Shi, J., Chen, Y., and Huang, K. (2023). New insights into the therapeutic potentials of statins in cancer. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1188926"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Zaky, M.Y., Fan, C., Zhang, H., and Sun, X.-F. (2023). Unraveling the Anticancer Potential of Statins: Mechanisms and Clinical Significance. Cancers, 15.","DOI":"10.3390\/cancers15194787"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s12033-023-01027-z","article-title":"Curcumin Promotes Diabetic Foot Ulcer Wound Healing by Inhibiting miR-152-3p and activating the FBN1\/TGF-\u03b2 Pathway","volume":"66","author":"Cao","year":"2024","journal-title":"Mol. Biotechnol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100725","DOI":"10.1016\/j.iotech.2024.100725","article-title":"A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models","volume":"23","author":"Tsimafeyeu","year":"2024","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2008.03.025","article-title":"Curcumin and cancer: An \u201cold-age\u201d disease with an \u201cage-old\u201d solution","volume":"267","author":"Anand","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Mansouri, K., Rasoulpoor, S., Daneshkhah, A., Abolfathi, S., Salari, N., Mohammadi, M., Rasoulpoor, S., and Shabani, S. (2020). Clinical effects of curcumin in enhancing cancer therapy: A systematic review. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07256-8"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kciuk, M., Gieleci\u0144ska, A., Mujwar, S., Ko\u0142at, D., Ka\u0142uzi\u0144ska-Ko\u0142at, \u017b., Celik, I., and Kontek, R. (2023). Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells, 12.","DOI":"10.3390\/cells12040659"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-12-2072","article-title":"Targeted Cancer Therapy with a 2-Deoxyglucose\u2013Based Adriamycin Complex","volume":"73","author":"Cao","year":"2013","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/mp900243b","article-title":"Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature","volume":"7","author":"Venditto","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Wang, H., Gao, C., Li, X., Chen, F., and Li, G. (2024). Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma. Sci. Rep., 14, Erratum in Sci. Rep. 2024, 14, 8787.","DOI":"10.1038\/s41598-024-57874-6"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Heider, C.G., Itenberg, S.A., Rao, J., Ma, H., and Wu, X. (2022). Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review. Biology, 11.","DOI":"10.3390\/biology11060817"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"825","DOI":"10.18632\/oncotarget.26582","article-title":"Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and \u03b3-irradiation in human glioblastoma cells","volume":"10","author":"Ivanov","year":"2019","journal-title":"Oncotarget"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e310322202888","DOI":"10.2174\/1570163819666220331095744","article-title":"Cancer Chemotherapy via Natural Bioactive Compounds","volume":"19","author":"Pathak","year":"2022","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/mdx526","article-title":"The use of antidepressants in oncology: A review and practical tips for oncologists","volume":"29","author":"Grassi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10495-019-01557-5","article-title":"Neuronal life or death linked to depression treatment: The interplay between drugs and their stress-related outcomes relate to single or combined drug therapies","volume":"24","author":"Solek","year":"2019","journal-title":"Apoptosis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/ijo.2016.3512","article-title":"Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells","volume":"49","author":"Zhao","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","article-title":"Collateral sensitivity as a strategy against cancer multidrug resistance","volume":"15","author":"Pluchino","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"105207","DOI":"10.1016\/j.phrs.2020.105207","article-title":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","volume":"163","author":"Tang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.21873\/anticanres.13669","article-title":"Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro","volume":"39","author":"Intuyod","year":"2019","journal-title":"Anticancer. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1249543","article-title":"Medicine. How thalidomide works against cancer","volume":"343","author":"Stewart","year":"2014","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.2174\/09298673113209990198","article-title":"Thalidomide-a notorious sedative to a wonder anticancer drug","volume":"20","author":"Zhou","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jpp\/rgab049","article-title":"Repurposing of sildenafil as antitumour; induction of cyclic guanosine monophosphate\/protein kinase G pathway, caspase-dependent apoptosis and pivotal reduction of Nuclear factor kappa light chain enhancer of activated B cells in lung cancer","volume":"73","author":"AboYoussef","year":"2021","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Haider, M., Elsherbeny, A., Pittal\u00e0, V., Fallica, A.N., Alghamdi, M.A., and Greish, K. (2021). The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. J. Pers. Med., 11.","DOI":"10.20944\/preprints202104.0679.v1"},{"key":"ref_100","first-page":"680","article-title":"Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent","volume":"10","author":"Pantziarka","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment","volume":"41","author":"Goitea","year":"2022","journal-title":"Oncogene"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Wang, Y., Hou, Y., Hou, L., Wang, W., Li, K., Zhang, Z., Du, B., and Kong, D. (2021). Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K\/AKT pathway. Biosci. Rep., 41.","DOI":"10.1042\/BSR20211056"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Tai, C.J., Yang, Y.H., Tseng, T.G., Chang, F.R., and Wang, H.C. (2021). Association between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study with Competing Risk Analysis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.564097"},{"key":"ref_104","first-page":"23","article-title":"Measuring IGF-1, ER-\u03b1 and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer","volume":"31","author":"Chong","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40265-024-02010-x","article-title":"Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?","volume":"84","author":"Buijs","year":"2024","journal-title":"Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhang, H., Zhu, Y., Wu, Z., Cui, C., and Cai, F. (2021). Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.654428"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/med.21870","article-title":"Salinomycin as a potent anticancer stem cell agent: State of the art and future directions","volume":"42","author":"Qi","year":"2022","journal-title":"Med. Res. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5604\/01.3001.0010.3801","article-title":"Metformin\u2014Its potential anti-cancer and anti-aging effects","volume":"71","author":"Podhorecka","year":"2017","journal-title":"Postep. Hig. Med. Dosw."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"FSO410","DOI":"10.2144\/fsoa-2019-0053","article-title":"Anticancer activity of metformin: A systematic review of the literature","volume":"5","author":"Aljofan","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2174\/1871520615666160504095040","article-title":"Disulfiram\u2019s Anticancer Activity: Evidence and Mechanisms","volume":"16","author":"Jiao","year":"2016","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1574892814666190514104035","article-title":"Repurposing Disulfiram as an Anti-Cancer Agent: Updated Review on Literature and Patents","volume":"14","author":"Ekinci","year":"2019","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"ref_112","first-page":"1","article-title":"The Rationality of Implementation of Dimethyl Sulfoxide as Differentiation-inducing Agent in Cancer Therapy","volume":"3","author":"Hoang","year":"2023","journal-title":"Cancer Diagn. Progn."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12935-015-0258-1","article-title":"Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells","volume":"15","author":"Osman","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1096\/fj.13-235440","article-title":"Unexpected low-dose toxicity of the universal solvent DMSO","volume":"28","author":"Galvao","year":"2014","journal-title":"FASEB J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7286737","DOI":"10.1155\/2019\/7286737","article-title":"Pro- and Antioxidant Effects of Vitamin C in Cancer in correspondence to Its Dietary and Pharmacological Concentrations","volume":"2019","author":"Pawlowska","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"G\u0119gotek, A., and Skrzydlewska, E. (2022). Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid. Antioxidants, 11.","DOI":"10.3390\/antiox11101993"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Uetaki, M., Tabata, S., Nakasuka, F., Soga, T., and Tomita, M. (2015). Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci. Rep., 5.","DOI":"10.1038\/srep13896"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Mussa, A., Mohd Idris, R.A., Ahmed, N., Ahmad, S., Murtadha, A.H., Tengku Din, T.A.D.A.A., Yean, C.Y., Wan Abdul Rahman, W.F., Mat Lazim, N., and Uskokovi\u0107, V. (2022). High-Dose Vitamin C for Cancer Therapy. Pharmaceuticals, 15.","DOI":"10.3390\/ph15060711"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zasowska-Nowak, A., Nowak, P.J., and Cia\u0142kowska-Rysz, A. (2021). High-Dose Vitamin C in Advanced-Stage Cancer Patients. Nutrients, 13.","DOI":"10.3390\/nu13030735"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6604554","article-title":"Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer","volume":"99","author":"Michelakis","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8201079","DOI":"10.1155\/2019\/8201079","article-title":"Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications","volume":"2019","author":"Tataranni","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00415-010-5654-9","article-title":"Severe encephalopathy and polyneuropathy induced by dichloroacetate","volume":"257","author":"Brandsma","year":"2010","journal-title":"J. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/15384047.2019.1632131","article-title":"Two dichloric compounds inhibit in vivo U87 xenograft tumor growth","volume":"20","author":"Ovcharenko","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41587-021-00999-0","article-title":"Negative innovation: When patents are bad for patients","volume":"39","author":"Feldman","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.34172\/ijhpm.2024.7494","article-title":"Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review","volume":"13","author":"Wang","year":"2024","journal-title":"Int. J. Health Policy Manag."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e19715","DOI":"10.2196\/19715","article-title":"Exploring Novel Funding Strategies for Innovative Medical Research: The HORAO Crowdfunding Campaign","volume":"22","author":"Schucht","year":"2020","journal-title":"J. Med. Internet Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e44197","DOI":"10.2196\/44197","article-title":"The Success of Cancer Crowdfunding Campaigns: Project and Text Analysis","volume":"25","author":"Zhang","year":"2023","journal-title":"J. Med. Internet Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.2105\/AJPH.2020.305768","article-title":"Crowdfunding Cannabidiol (CBD) for Cancer: Hype and Misinformation on GoFundMe","volume":"110","author":"Zenone","year":"2020","journal-title":"Am. J. Public Health"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Vora, L.K., Gholap, A.D., Jetha, K., Thakur, R.R.S., Solanki, H.K., and Chavda, V.P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071916"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/CCO.0000000000001068","article-title":"Potential application of artificial intelligence in cancer therapy","volume":"36","author":"Riaz","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Islam, R., and Tarique, M. (2024). Artificial Intelligence (AI) and Nuclear Features from the Fine Needle Aspirated (FNA) Tissue Samples to Recognize Breast Cancer. J. Imaging, 10.","DOI":"10.3390\/jimaging10080201"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Ziegelmayer, S., Marka, A.W., Strenzke, M., Lemke, T., Rosenkranz, H., Scherer, B., Huber, T., Weiss, K., Makowski, M.R., and Karampinos, D.C. (2024). Speed and efficiency: Evaluating pulmonary nodule detection with AI-enhanced 3D gradient echo imaging. Eur. Radiol., ahead of print.","DOI":"10.1007\/s00330-024-11027-5"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13046-024-03111-x","article-title":"Targeting treatment resistance: Unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy","volume":"43","author":"Zhou","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Pasha, S.A., Khalid, A., Levy, T., Demyan, L., Hartman, S., Newman, E., Weiss, M.J., King, D.A., Zanos, T., and Melis, M. (2024). Machine learning to predict completion of treatment for pancreatic cancer. J. Surg. Oncol.","DOI":"10.1002\/jso.27812"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Goumas, G., Dardavesis, T.I., Syrigos, K., Syrigos, N., and Simou, E. (2024). Chatbots in Cancer Applications, Advantages and Disadvantages: All that Glitters Is Not Gold. J. Pers. Med., 14.","DOI":"10.3390\/jpm14080877"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1237\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:00:46Z","timestamp":1760112046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":135,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["pharmaceutics16091237"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16091237","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}